Discovery of a Potent, Selective, and Orally Available PI3K delta Inhibitor for the Treatment of Inflammatory Diseases.
Erra, M., Taltavull, J., Greco, A., Bernal, F.J., Caturla, J.F., Gracia, J., Dominguez, M., Sabate, M., Paris, S., Soria, S., Hernandez, B., Armengol, C., Cabedo, J., Bravo, M., Calama, E., Miralpeix, M., Lehner, M.D.(2017) ACS Med Chem Lett 8: 118-123
- PubMed: 28105286 
- DOI: https://doi.org/10.1021/acsmedchemlett.6b00438
- Primary Citation of Related Structures:  
5M6U - PubMed Abstract: 
The delta isoform of the phosphatidylinositol 3-kinase (PI3Kδ) has been shown to have an essential role in specific immune cell functions and thus represents a potential therapeutic target for autoimmune and inflammatory diseases. Herein, the optimization of a series of pyrrolotriazinones as potent and selective PI3Kδ inhibitors is described. The main challenge of the optimization process was to identify an orally available compound with a good pharmacokinetic profile in preclinical species that predicted a suitable dosing regimen in humans. Structure-activity relationships and structure-property relationships are discussed. This medicinal chemistry exercise led to the identification of LAS191954 as a candidate for clinical development.
Organizational Affiliation: 
Medicinal Chemistry and Screening, Pharmacokinetics and Metabolism, Systems Biology, and Respiratory Therapeutic Area, Almirall R&D , Barcelona 08980, Spain.